CDX-3379, an anti-ErbB3 monoclonal antibody, showed promising molecular and antitumor activity in head and neck squamous cell carcinoma (HNSCC) as a monotherapy or in combination with cetuximab. Here, ERBB3 is linked to head and neck squamous cell carcinoma.